依据《上海证券交易所股票上市规则》9.3.2条规定，公司2023年年度报告披露后，公司股票可能被上海证券交易所实施退市风险警示(在公司股票简称前冠以“*ST”字样)。Dali Pharmaceutical (603963.SH) issued an announcement. The company's stock will be traded from March 12 to 202, 2024...
Zhitong Finance App News, Dali Pharmaceutical (603963.SH) announced that the company's stock trading closed for 7 consecutive trading days from March 12, 2024 to March 20, 2024, with a cumulative increase of 94.90%. The short-term increase was significantly higher than that of the same industry and the Shanghai Composite Index, with a cumulative turnover rate of 69%. Among them, abnormal stock trading fluctuations as stipulated in the “Shanghai Stock Exchange Trading Rules” were met three times on March 13, 2024, March 15, 2024, and March 19, 2024.
According to preliminary estimates by the finance department, the company expects to achieve net profit attributable to owners of the parent company in 2023 of 22 million yuan to -18 million yuan, and net profit attributable to owners of the parent company after deducting non-recurring profit and loss of -27 million yuan to 22 million yuan. It is estimated that the operating income will be 83 million yuan to 92 million yuan in 2023, and the operating income after deducting business income unrelated to the main business and income without commercial substance will be 82 million yuan to 91 million yuan, which is less than 100 million yuan.
According to section 9.3.2 of the “Shanghai Stock Exchange Stock Listing Rules”, after the disclosure of the company's 2023 annual report, the company's stock may be subject to a delisting risk warning by the Shanghai Stock Exchange (with the word “*ST” before the company's stock abbreviation).
